[Source: KOLD] – The Food and Drug Administration has told Glenmark Generics of Mahwah, N.J. and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets.
The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3-, 0.4- and 0.6-mg dosages.
Konec’s web site for its facility at 3840 E 44th St. says its products include five different varieties of nitroglycerin sublingual tablets manufactured for Glenmark Generics.
For more information: FDA orders Tucson firm to stop selling unapproved heart meds